Drug Type Small molecule drug |
Synonyms Uptava, 업타바서방정 |
Target |
Action inhibitors, agonists |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PPARα agonists(Peroxisome proliferator-activated receptor α agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (25 Feb 2026), |
Regulation- |
Molecular FormulaC22H28ClNO5 |
InChIKeyJWAZHODZSADEHB-UHFFFAOYSA-M |
CAS Registry856676-23-8 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Coronary Disease | South Korea | 25 Feb 2026 |





